Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review reports no new clinical results but summarizes the therapeutic potential of Aloe-derived extracellular vesicles in tissue repair, highlighting both promising mechanisms and the need for further research into their clinical application.

In this study of women with breast cancer undergoing chemotherapy and scalp cooling, 12% experienced incomplete hair regrowth at 6 months, with tamoxifen therapy identified as a significant risk factor for persistent chemotherapy-induced alopecia.

In this Delphi study, international experts established consensus-based guidelines for diagnosing and managing persistent chemotherapy-induced alopecia (pCIA), recommending prevention through scalp cooling and early use of minoxidil, while advising against bicalutamide and certain finasterides for breast cancer patients due to safety concerns.

This opinion piece discusses strategies for managing cancer-related alopecia, emphasizing personalized approaches including scalp cooling and topical minoxidil, but it reports no new clinical results.

This study found that topical Dithranol 0.5% is more effective than topical Tacrolimus 0.1% for hair regrowth in patients with alopecia areata, with 40% of Dithranol-treated patients showing over 80% hair regrowth compared to 23.33% for Tacrolimus-treated patients.

This review discusses the various off-label treatments for alopecia areata, highlighting that these therapies may promote hair growth but are not curative.

This article reviews treatment options for Alopecia Areata, concluding that topical corticosteroids are effective for mild cases, while systemic therapies are advised for moderate to severe cases.

This article discusses psoriasis, highlighting its common triggers, such as trauma and infections, and potential treatment options ranging from topical therapies to systemic medications like methotrexate for severe cases.

In this study, scalp cooling therapy was found to be well tolerated and effective at improving hair preservation for Asian women with breast or gynecological cancers undergoing certain chemotherapy regimens, particularly weekly paclitaxel, compared to historical controls.

This review discusses the challenges in treating alopecia areata and the potential psychological impact, noting that spontaneous hair regrowth often occurs and highlighting the consideration of psychotherapy alongside treatment options; it reports no new experimental results.

This consensus statement from Saudi Arabia outlines evidence- and experience-based recommendations for diagnosing and managing alopecia areata, focusing on severity assessment, prognostic indicators, and therapeutic options, with special attention to pediatric patients and uncommon cases.

This study conducted a comprehensive pharmacognostic and phytochemical analysis of Sphagneticola calendulacea stem, identifying tannin-filled cells, various secondary metabolites, and significant physicochemical characteristics, which could aid in authenticating the plant for therapeutic use.

This source reports that clinical trials found oral baricitinib significantly improved hair regrowth in patients with severe alopecia areata, with 38.8% achieving at least 80% scalp hair coverage after 36 weeks on a 4-mg dose, compared to 6.2% with placebo in trial 1.

This review discusses the phytochemistry and pharmacological properties of Martynia annua but reports no new findings; it suggests the plant's various phytoconstituents offer scope for future research.

This study found that scalp cooling effectively prevented chemotherapy-induced alopecia in patients, with a higher success rate observed in those who did not receive anthracyclines, although some experienced scalp pain and other mild adverse effects.

This case report highlights an unusual trichoscopic appearance in alopecia areata due to dithranol staining, which may obscure typical patterns and reveal atypical vascular features in the interfollicular spaces.

This study evaluated current treatments for pediatric alopecia areata and found that high potency topical steroids had the strongest supporting evidence, with promising results also observed for anthralin ointment and other treatments in lower-grade studies.

In this study, researchers will conduct a randomized, double-blind, multi-center clinical trial to assess the effectiveness of YH0618 granule in preventing chemotherapy-induced hair loss among breast cancer patients, aiming to understand its mechanism related to kidney deficiency in Chinese Medicine. Results are not yet reported.

The document concludes that various topical medications are effective for skin conditions but often cause skin irritation as a side effect.

This review examines the clinical presentation and management strategies for alopecia areata, focusing on pediatric patients, and highlights the need for addressing its psychological impacts; it reports no new clinical findings.

The document discusses various treatments for different types of hair loss, including steroids, minoxidil, and anthralin.

This review examines current treatment options for alopecia areata and highlights the challenges due to limited evidence-based data and unpredictability in disease progression.

Alopecia areata is relatively common in children, has a variable course, and shows different responses to treatment; thyroid testing is recommended for those affected.

This study found that women with late onset acne have fewer comedones and acne lesions compared to those with early onset, despite no differences in P. acnes density or sebum secretion.

This study reports that blocking the epidermal growth factor receptor in cancer treatments can lead to changes in hair growth and create a "wavy" hair phenotype in some patients.

This article describes the anatomy and life cycle of hair follicles, explaining how disruptions in the hair growth cycle can lead to various forms of alopecia.

This review examines existing and potential treatments for alopecia areata but does not report new clinical results, emphasizing the need for future therapies that target immune pathways or protect hair follicles from inflammation.

Topical minoxidil and anthralin work for patchy alopecia areata but not for alopecia totalis/universalis.

This article reviews therapeutic advances published between December 1986 and December 1987 but reports no new research findings; readers are advised to consult the original articles before considering new therapies.

This case report details a 2-year-old boy who developed generalized hypertrichosis after using 5% minoxidil foam for alopecia areata, highlighting the importance of caution and proper administration instructions for young children.